stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Free cash flow
Beam Therapeutics Inc.'s free cash flow for fiscal 2025 was −$360.0M, compared with −$356.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$398.2M. Over the past ten years it has ranged from −$360.0M (fiscal 2025) to −$2.7M (fiscal 2017) — the current reading is the lowest in ten years. Free cash flow has fallen for 3 consecutive fiscal years. Beam Therapeutics Inc. ranks 582nd of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$360.0M | — |
| FY2024 | −$356.2M | — |
| FY2023 | −$182.9M | — |
| FY2022 | −$26.4M | — |
| FY2021 | −$113.1M | — |
| FY2020 | −$112.1M | — |
| FY2019 | −$84.5M | — |
| FY2018 | −$33.4M | — |
| FY2017 | −$2.7M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$112.0M | — |
| Jun 2026 | −$68.5M | — |
| Mar 2026 | −$130.7M | — |
| Dec 2025 | −$87.0M | — |
| 28 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | −$4.4M |
| MBX MBX Biosciences, Inc. compare | −$85.2M |
| NAMS NewAmsterdam Pharma Company N.V. compare | −$150.9M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −$196.9M |
| XNCR Xencor, Inc. compare | −$208.3M |
| VRDN Viridian Therapeutics, Inc. compare | −$343.4M |
| IDYA IDEAYA Biosciences, Inc. compare | −$349.8M |
| BEAM Beam Therapeutics Inc. | −$398.2M |
| RCUS Arcus Biosciences, Inc. compare | −$465.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement